Digital care plan for adults with advanced sarcoma receiving systemic treatment
Tests a digital care plan alongside standard care in adults with advanced sarcoma.
Plain-language title generated from the registry record
Registry title: Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
Key facts
- Where
- Besançon, Lille, Lyon, Paris, Poitiers, Rennes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, and Villejuif, FranceSee the 11 sites
Where in France
- Chu Jean MinjozBesançon, FranceTaking people
- Centre Oscar LambretLille, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- Hôpital Pitié-Salpêtrière - AP-HPParis, FranceNot yet recruiting
- CHU de PoitiersPoitiers, FranceTaking people
- Centre Eugène MarquisRennes, FranceNot yet recruiting
- Institut de Cancérologie de l'OuestSaint-Herblain, FranceTaking people
- Centre Paul StraussStrasbourg, FranceTaking people
- Institut Claudius RegaudToulouse, FranceNo longer taking part
- Institut de Cancérologie de LorraineVandœuvre-lès-Nancy, FranceNot yet recruiting
- Gustave RoussyVillejuif, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Oscar Lambret
- Trial code
- NCT06211257
- Record updated
- 18 March 2026
- Original description
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.Read full original descriptionShow less
Phase 3 Superiority Trial Evaluating the Benefit of Dematerialized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment for Metastatic or Locally Advanced Disease.
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.
Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone.
All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.
Inclusion: Sarcomas of soft tissues or viscera ; Inoperable metastatic or locally advanced disease ; Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ; Patient covered by French social security ; Written, signed, informed consent .
Exclusion: Prior inclusion in ePPS trial for a prior systemic treatment ; Poor understanding of French ; Difficulty accessing a computer ; Pregnant or nursing woman ; Person deprived of liberty or under guardianship ; Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.